The Benefits of Neuroids /Neuropeptides in Combating , Neurological, and Ocular Diseases.
Keywords:
betaine, choline, citicoline, neurological dysfunction, neuroids, neuroprptides, phosphatidylcholine
Abstract
Neuroids and neuropeptides (ND/NPs) are drugs with promising efficacy in cerebrovascular diseases. In this article the benefits and mechanisms of action of ND/NPs for stroke are reviewed in light of the pathogenesis of stroke. The primary mechanism is that ND/NPs help in the synthesis of acetylcholine and betaine. These, in turn, work to help in the formation of nerve cell membrane phospholipids and attenuate the production of free radicals. This is important in stroke because brain damage after stroke is associated with excess production of free radicals. Furthermore, ND/NPs may stimulate the activity of glutathione reductase and have the ability to promote learning and improve cognitive impairment. Pharmacokinetics suggests that ND/NPs are well absorbed, with a higher degree of bioavailability when administered orally. A dose of 500 mg to 2,000 mg per day in slow releasing form is an effective regimen based on clinical trials, and is safe for use in elderly population and pediatrics.
Downloads
- Article PDF
- TEI XML Kaleidoscope (download in zip)* (Beta by AI)
- Lens* NISO JATS XML (Beta by AI)
- HTML Kaleidoscope* (Beta by AI)
- DBK XML Kaleidoscope (download in zip)* (Beta by AI)
- LaTeX pdf Kaleidoscope* (Beta by AI)
- EPUB Kaleidoscope* (Beta by AI)
- MD Kaleidoscope* (Beta by AI)
- FO Kaleidoscope* (Beta by AI)
- BIB Kaleidoscope* (Beta by AI)
- LaTeX Kaleidoscope* (Beta by AI)
How to Cite
References
Susan Margulies, Gail Anderson, Fahim Atif, Jerome Badaut, Robert Clark, Philip Empey, Maria Guseva, Michael Hoane, Jimmy Huh, Jim Pauly, Ramesh Raghupathi, Stephen Scheff, Donald Stein, Huiling Tang, Mona Hicks (2016) Combination Therapies for Traumatic Brain Injury: Retrospective Considerations. 33(1), 101-112.
Junko Morita, Kuniyuki Kano, Kazuki Kato, Hiroyuki Takita, Hideki Sakagami, Yasuo Yamamoto, Emiko Mihara, Hirofumi Ueda, Takanao Sato, Hidetoshi Tokuyama, Hiroyuki Arai, Hiroaki Asou, Junichi Takagi, Ryuichiro Ishitani, Hiroshi Nishimasu, Osamu Nureki, Junken Aoki (2016) Structure and biological function of ENPP6, a choline-specific glycerophosphodiester-phosphodiesterase. 6(1).
Samo Ribarič (2016) The Rationale for Insulin Therapy in Alzheimer's Disease. 21(6), 689.
C Edward, Jauchec (2017) Ischemic Stroke Clinical Presentation.
Maria Luca, Antonina Luca, Carmela Calandra (2015) The Role of Oxidative Damage in the Pathogenesis and Progression of Alzheimer's Disease and Vascular Dementia. 2015, 1-8.
D Liebeskind, O' Connorre (2017) Hemorrhagic Stroke Clinical Presentation.
Seyedhossein Ojaghihaghighi, Samad Vahdati, Akram Mikaeilpour, Ali Ramouz (2017) Comparison of neurological clinical manifestation in patients with hemorrhagic and ischemic stroke. 8(1), 34.
Silvia Vincenzetti, Valeria Polzonetti, Daniela Micozzi, Stefania Pucciarelli (2016) Enzymology of Pyrimidine Metabolism and Neurodegeneration. 23(14), 1408-1431.
Mallikarjunarao Ganesana, Scott Lee, Ying Wang, B Venton (2016) Analytical Techniques in Neuroscience: Recent Advances in Imaging, Separation, and Electrochemical Methods. 89(1), 314-341.
Gelu Onose, Cristina Daia, Monica Haras, Tiberiu Spircu, Aurelian Anghelescu, Ciurea, Anca Mihaescu, Liliana Onose (2011) A long-term, complex, unitary appraisal regarding neurorestorative, including neurorehabilitative, outcomes in patients treated with Cerebrolysin®, following traumatic brain injury. 18(1), 85.
Bin-Yin Li, Ying Wang, Hui-Dong Tang, Sheng-Di Chen (2017) The role of cognitive activity in cognition protection: from Bedside to Bench. 6(1), 7.
Edward Walter, Mike Carraretto (2016) The neurological and cognitive consequences of hyperthermia. 20(1), 199.
Pawel Grieb, Anselm Jünemann, Marek Rekas, Robert Rejdak (2016) Citicoline: A Food Beneficial for Patients Suffering from or Threated with Glaucoma. 8.
Khanh Bui, Fahua She, Michael Hutchison, Åsa Brunnström, Mark Sostek (2015) Absorption, distribution, metabolism, and excretion of [14C]-labeled naloxegol in healthy subjects. 53(10), 838-846.
Kewal Jain (2011) Neuroprotective Agents. 25-139.
Zeltzin Ceja-Galicia, Alberto Daniel, Ana Salazar, Pablo Pánico, Patricia Ostrosky-Wegman, Andrea Díaz-Villaseñor (2017) Effects of arsenic on adipocyte metabolism: Is arsenic an obesogen?. 452, 25-32.
Henry Querfurth, Frank Laferla (2010) Alzheimer's Disease. 362(4), 329-344.
M Prins, T Greco, D Alexander, C Giza (2013) The pathophysiology of traumatic brain injury at a glance. 6(6), 1307-1315.
Patricia Tagliaferro, Robert Burke (2016) Retrograde Axonal Degeneration in Parkinson Disease. 6(1), 1-15.
Deepdiveadmin (2015) LAS VEGAS SANDS CORP., a Nevada corporation, Plaintiff, v. UKNOWN REGISTRANTS OF www.wn0000.com, www.wn1111.com, www.wn2222.com, www.wn3333.com, www.wn4444.com, www.wn5555.com, www.wn6666.com, www.wn7777.com, www.wn8888.com, www.wn9999.com, www.112211.com, www.4456888.com, www.4489888.com, www.001148.com, and www.2289888.com, Defendants.. 20(10), 859-868.
K Bonsu, I Owusu, K Buabeng, D Reidpath, A Kadirvelu (2016) Review of novel therapeutic targets for improving heart failure treatment based on experimental and clinical studies. 12, 887.
Isin Kulaksizoglu (2007) Mood and Anxiety Disorders in Patients with Myasthenia Gravis. 21(6), 473-481.
N Volkow, G-J Wang, J Logan, D Alexoff, J Fowler, P Thanos, C Wong, V Casado, S Ferre, D Tomasi (2015) Caffeine increases striatal dopamine D2/D3 receptor availability in the human brain. 5(4), e549-e549.
H Danesh-Meyer, L Levin (2015) Glaucoma as a neurodegenerative disease. 35, 22-28.
Jagat Kanwar, Sriramoju, Kanwar (2012) Neurological disorders and therapeutics targeted to surmount the blood-brain barrier. 7, 3259.
P Lapchak, J Zhang (2017) Neuroprotective Therapy for Stroke and Ischemic Disease.
Published
2017-11-22
Issue
Section
License
Copyright (c) 2017 Authors and Global Journals Private Limited
This work is licensed under a Creative Commons Attribution 4.0 International License.